Skip to content
buyNotable cluster of 4

Bain Capital Life Sciences Investors, LLC bought $9.9M of KYTX

owner at Kyverna Therapeutics, Inc.. 450,000 shares at an average of $22.00, traded Feb 12, 2024, filed Feb 14, 2024.

Conviction score
60
Value
$9.9M
450,000 shares
Holdings after
3,163,868
+17% from before
From 52-week low
0%
low $29.93, close $29.93
From 52-week high
-1%
high $30.10, as of Feb 12, 2024

Score components

  • Role
    10% owner
    +12
  • Trade size
    $9.9M at market
    +25
  • Relative to holdings
    Holdings up 17%
    +3
  • Price context
    0% above the 52-week low
    +10
  • Cluster
    4 insiders buying within 14 days
    +15
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (2 with prices)
    0
  • Outside holder
    A 10% owner who is not an officer or director
    -5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -0.6%, 3m -46.9%, 6m -77.4%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

KYTXOct 13, 2026 · close 5.77
Since filing Feb 14, 2024: -80.7%SPY +61.2% · excess -141.9%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000950170-24-015358, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 12, 2024CConversion
Common Stockindirect: See footnotes
+2,713,868--2,713,868Feb 14, 2024
Feb 12, 2024POpen-market purchase
Common Stockindirect: See footnotes
+450,000$22.00$9.9M3,163,868Feb 14, 2024
Feb 12, 2024CConversion
Series B Convertible Preferred Stockderivativeindirect: See footnotes
-12,351,087$0.00$00Feb 14, 2024

Related signals

Other insiders at Kyverna Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
43Moderate
KYTXbuy 2
Kyverna Therapeutics, Inc.
Westlake BioPartners Opportunity Fund I, L.P.
owner
$1000k
133,333 shares
+18%
51Moderate
KYTXbuy 2
Kyverna Therapeutics, Inc.
Beth C Seidenberg
director
$1000k
133,333 shares
+18%
14Weak
KYTXsell10b5-1
Kyverna Therapeutics, Inc.
Karen Marie Walker
Chief Technology Officer
$293k
23,998 shares
-51%
65Notable
KYTXbuy 4
Kyverna Therapeutics, Inc.
Vida Ventures, LLC
owner
$5.6M
253,136 shares
-
58Moderate
KYTXbuy 4
Kyverna Therapeutics, Inc.
Gilead Sciences, Inc.
owner
$20M
910,000 shares
+28%
66Notable
KYTXbuy 4
Kyverna Therapeutics, Inc.
Northpond Ventures III GP, LLC
other
$9.9M
450,000 shares
-

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.